All In Biotech

Drug Trial Radar · NCT06989645

A Phase 1/2a Study to Evaluate Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis

A Prospective, Double-blinded, Randomized, Placebo-controlled Phase 1/2a Study to Assess Safety, Tolerability, Systemic Exposure, and Preliminary Efficacy of Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Aug 19, 2025

Primary completion

Feb 2, 2026

Study completion Mar 2, 2026

Sponsor

Lead sponsor
Synartro ABIndustry
Sponsor type
Industry
Collaborators
CTC Clinical Trial Consultants AB
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a, phase 1/2a trial, to assess the safety, tolerability, systemic exposure as well as preliminary efficacy following a single intra-articular injection of 3 dose levels of SYN321 in patients with symptomatic knee osteoarthritis (KOA).

Conditions

  • Osteoarthritis of Knee

Interventions

  • SYN321Drug

    Intra-articular

  • PlaceboDrug

    Intra-articular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and intensity of adverse eventsTime frame: From IMP injection (day 1) until end of trial visit (day 56)
  2. Clinically significant changes in ECGTime frame: From screening until end of trial visit (day 56)
  3. Clinically significant changes in blood pressureTime frame: From screening until end of trial visit (day 56)
  4. Clinically significant changes in heart rateTime frame: From screening until end of trial visit (day 56)
  5. Clinically significant changes in body temperatureTime frame: From screening until end of trial visit (day 56)
  6. Clinically significant changes in Clinical Laboratory ProfileTime frame: From screening until end of trial visit (day 56)
  7. Clinically significant changes in urine analysisTime frame: From screening until end of trial visit (day 56)
  8. Clinically significant changes in Physical ExaminationTime frame: From screening until end of trial visit (day 56)
  9. Clinically significant changes of local tolerability reactionsTime frame: From screening until end of trial visit (day 56)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cinical Trial Consultants AB

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.